Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health Inc. (NYSE: HIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's ...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a ...